PVH
CRNX icon

Psagot Value Holdings’s Crinetics Pharmaceuticals CRNX Stock Holding History

Psagot Value Holdings’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,500
Closed -$46K – 509
2022
Q4 		$46K Buy
+2,500
New +$44.1K 0.01% 275

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Psagot Value Holdings's CRNX Position: Q1 2023 in Review

Psagot Value Holdings sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2023, closing a stake of 2,500 shares — an estimated $46K sold.

Psagot Value Holdings first reported a position in CRNX in Q4 2022 and held it in 1 quarter. The position peaked at $46K in Q4 2022. 128 funds tracked by Wall St. Rank hold CRNX as of Q1 2023.

  • Psagot Value Holdings reported no remaining Crinetics Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Psagot Value Holdings sold 2,500 Crinetics Pharmaceuticals shares in Q1 2023, an estimated $46K.
  • Psagot Value Holdings first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Psagot Value Holdings's Crinetics Pharmaceuticals position peaked at $46K in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2023.

Based on Psagot Value Holdings's 13F filing for Q1 2023, filed 20 Jun 2023.